SCANCELL HLDGS ORD 0.1P (LSE:SCLP)

 

SCANCELL HLDGS ORD 0.1P (SCLP.L, LSE, LSE:SCLP)

SCLP Share PerformanceMore

52 week high40.490 30/10/14
52 week low27.850 06/08/14
52 week change -3.250 (-9.15%)
4 week volume4,352,281 25/11/14

Media for (SCLP)

Presenter: Mike Mitchell, Director, Equity Research
11/12/2014
Presenter: Dr Richard Goodfellow
10/12/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 8294Z Scancell Holdings Plc 15 December 2014 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Scancell Holdings plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An...

Scancell Holdings - Analyst Interview, Panmure Gordon

Half Yearly Report

RNS Number: 3125Z Scancell Holdings Plc 10 December 2014 10 December 2014 Scancell Holdings Plc Interim Results for the six months ended 31 October 2014 SCIB1 continues to generate highly encouraging survival data; Modi-1 vaccine on track for 2016 entry into clinic Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for th...

Scancell Holdings - Half yearly report

Change of Registered Office

RNS Number: 0354V Scancell Holdings Plc 22 October 2014 22 October 2014 Scancell Holdings Plc ('Scancell') Change of Registered Office Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, announces the change of the Company's registered office to: Eversheds House 70 Great Bridgewater Street Manchester M1 5E...

Result of AGM

RNS Number: 3189U Scancell Holdings Plc 14 October 2014 14 October 2014 Scancell Holdings Plc ('Scancell') Results of AGM Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that all resolutions proposed at the Annual General Meeting held today were duly passed. For Further Information: Dr Richard ...

Scancell appoints Nomad and broker

Scancell Holdings, the developer of novel immunotherapies for the treatment of cancer, has appointed Panmure Gordon (U...

Appointment of Nominated Adviser and Broker

RNS Number: 1804U Scancell Holdings Plc 14 October 2014 14 October 2014 Scancell Holdings Plc ('Scancell') Appointment of Nominated Adviser and Broker Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer has appointed Panmure Gordon (UK) Limited as its Nominated Adviser and Broker with immediate effec...